Hyperphosphatemia

Phosphorus Content Higher in Packaged Meats Listing Phosphate Additives

Phosphorus Content Higher in Packaged Meats Listing Phosphate Additives

By

Additives in packaged meat, poultry, and fish can contribute significantly to the dietary phosphorus and potassium loads in CKD patients, researchers say.

Phosphorus Control by Dietary Restriction May Lead to Malnutrition

Phosphorus Control by Dietary Restriction May Lead to Malnutrition

By

The use of phosphate binders to manage hyperphosphatemia in maintenance hemodialysis patients might allow diets less restricted in protein and calories, according to a study.

Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer

Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer

By

Serum phosphorus fell to similar levels in two-thirds of peritoneal dialysis patients, but sucroferric oxyhdroxide recipients had a lower pill burden.

Niacin's Phosphate-Lowering Ability Modest

Niacin's Phosphate-Lowering Ability Modest

By

In a study of patients with chronic kidney disease and cardiovascular disease, niacin therapy lowered serum phosphate by just 0.25 mg/dL over 3 years compared with placebo.

Phosphate Binder Use Tied With Better Survival

Phosphate Binder Use Tied With Better Survival

By

Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.

Reducing Phosphorus Improves Survival

Reducing Phosphorus Improves Survival

By

Achieving a phosphate value of 1.4 mmol/L seemed optimal.

Phosphate Binder Reduces FGF23 in CKD Patients

Phosphate Binder Reduces FGF23 in CKD Patients

By

Patients with non-dialysis chronic kidney disease and iron deficiency anemia treated with ferric citrate experienced significant declines in FGF23 regardless of change in serum phosphorus.

In-Hospital Mortality Linked to High, Low Phosphorus

In-Hospital Mortality Linked to High, Low Phosphorus

By

Admission serum phosphorus levels below 2.5 and 4.9 mg/dL and above are associated with increased odds of dying in the hospital.

Sucroferric Oxyhydroxide Improves Phosphorus Control

Sucroferric Oxyhydroxide Improves Phosphorus Control

By

After switching to sucroferric oxyhydroxide, a higher proportion of patients achieved in-range serum phosphorus levels.

Distinct Phosphate Targets Feasible, Pilot Study Shows

Distinct Phosphate Targets Feasible, Pilot Study Shows

By

A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.

High Phosphorus Ups Risk of Kidney Transplant Failure, Death

High Phosphorus Ups Risk of Kidney Transplant Failure, Death

By

Each 1-mg/dL increase in serum phosphorus among kidney transplant recipients is associated with 36% and 21% increased risk in graft failure and death, respectively.

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

By

Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.

Sodium Phosphate Enemas Do Not Worsen Renal Function

Sodium Phosphate Enemas Do Not Worsen Renal Function

By

Creatinine, phosphorus, and electrolyte levels were not significantly different for exposed and unexposed hospitalized patients.

Nutritional Status Affects Phosphorus-Mortality Link in Hemodialysis

Nutritional Status Affects Phosphorus-Mortality Link in Hemodialysis

By

New findings suggest that nutritional index should be considered in the management of phosphorus level in HD patients, researchers conclude.

Researchers: Iron-based Binders Best for Hyperphosphatemia

Researchers: Iron-based Binders Best for Hyperphosphatemia

By

Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

By

Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.

Short-term Interleukin Inhibition Ineffective in CKD-MBD

Short-term Interleukin Inhibition Ineffective in CKD-MBD

By

Serum phosphorus and intact parathyroid hormone levels were not reduced with 12 weeks of rilonacept therapy.

Hyperphosphatemia May Predict Diastolic Dysfunction in CKD

Hyperphosphatemia May Predict Diastolic Dysfunction in CKD

By

CKD patients with and without diastolic dysfunction had average serum phosphate levels of 7.3 and 5.5 mg/dL, respectively.

Iron-based Binder Improves Phosphorus Levels in Dialysis Patients

Iron-based Binder Improves Phosphorus Levels in Dialysis Patients

By

The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.

Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival

Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival

By

Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.

Guidelines for CKD Mineral and Bone Disorder Updated

Guidelines for CKD Mineral and Bone Disorder Updated

By

Among other changes, the new KDIGO guidelines highlight the potential dangers of hypercalcemia.

Hip Fracture Rates Falling Among ESRD Patients

Hip Fracture Rates Falling Among ESRD Patients

From 2003 to 2011 there was a 26.7% decrease in in-hospital mortality rate after hip fracture.

Education Can Improve Phosphate Control

Education Can Improve Phosphate Control

By

Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.

Switch to an Iron-Based Binder Found to Improve Phosphorus Lowering

Switch to an Iron-Based Binder Found to Improve Phosphorus Lowering

By

Converting hemodialysis patient to sucroferric oxyhydroxide from a previous binder increased the proportion of patients achieving target serum phosphorus levels.

Reducing Serum Phosphorus to Safer Target Range Ups Survival

Reducing Serum Phosphorus to Safer Target Range Ups Survival

By

Survival improved by 12% when serum phosphate levels approached a safer target range.

Residual Kidney Function Predicts Mortality in CKD-MBD

Residual Kidney Function Predicts Mortality in CKD-MBD

By

In a study of hemodialysis patients, mortality risk increased along with phosphorus level, particularly among patients with higher residual renal urea clearance.

Initial Low-Dose Etelcalcetide Feasible for SHPT Patients

Initial Low-Dose Etelcalcetide Feasible for SHPT Patients

By

At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.

Sucroferric Oxyhydroxide Ups Phosphorus Control in SHPT

Sucroferric Oxyhydroxide Ups Phosphorus Control in SHPT

By

Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.

Eliminating Phosphorus Food Additives Does Not Compromise Nutrition

Eliminating Phosphorus Food Additives Does Not Compromise Nutrition

By

Replacing foods containing phosphorus-based additives with similar foods not containing these additives can control hyperphospatemia without interfering with nutritional status.

ALP Predicts Mortality in Peritoneal Dialysis Patients With CKD-MBD

ALP Predicts Mortality in Peritoneal Dialysis Patients With CKD-MBD

By

Alkaline phosphatase was more strongly linked to mortality compared with other biomarkers of chronic kidney disease-mineral and bone disorder.

Sign Up for Free e-newsletters